An Irvine drug maker, Spectrum Pharmaceuticals Inc., has said that it got regulatory approval for an expanded use of a cancer drug.
Spectrum said that the FDA approved Zevalin as an early treatment for a blood cancer, in patients with non-Hodgkin's lymphoma. The drug was used previously on patients whose tumors did not respond to other treatments.
Spectrum Pharmaceuticals and Cell Therapeutics have entered into an agreement to form a 50:50 owned joint venture, RIT Oncology, to commercialize and develop Zevalin in the United States.
- Google Nexus 10 2 launch date reportedly delayed to 2014
- Ford unveils new 2015 Mustang in its first global launch
- Ford set to unveil its all-new 2015 Mustang --- the first Mustang to be sold globally
- Finnish startup Jolla Oy launches its self-titled Jolla headset in Europe
- HTC to launch dual-SIM variant of flagship HTC One handset in UK